KIF20A and pancreatic adenocarcinoma: More interestingly, in a phase I clinical trial, researchers combined a KIF20A-derived peptide with GEM as a novel immunotherapeutic agent to treat advanced PAAD patients and achieved longer overall survival, suggesting the role of KIF20A as an anticancer therapeutic target and the possibility of modulating GEM sensitivity (Suzuki et al., 2014).